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Abstract
Rationale The mechanisms underlying individual differ-
ences in the response to serotonergic drugs are poorly
understood. Rat studies may contribute to our knowledge of
the neuronal substrates that underlie these individual
differences.
Objectives A pharmacobehavioural study was performed to
assess individual differences in the sensitivity to serotoner-
gic drugs in rats that were selected based on their response
to a novel environment.
Methods Low responders (LR) and high responders (HR)
to novelty rats were tested on the elevated T-maze
following systemic injections of increasing doses of various
serotonergic agents. The duration of avoidance of the open
arms was scored for five trials.
Results The duration of avoidance behaviour was larger in
saline-treated LR rats compared to saline-treated HR rats.
The 5-HT1A agonist 8-OH-DPAT and the 5-HT2 agonists
mCPP and DOI decreased the duration of avoidance
behaviour in LR rats, but increased it in HR rats. The 5-
HT3 agonist SR57227A and the 5-HT releaser/reuptake
inhibitor d-fenfluramine increased the duration of avoid-
ance behaviour in both types of rat. However, higher doses
of SR57227Awere required to alter avoidance behaviour in
HR than in LR rats. The onset of the effects of SR57227A,
d-fenfluramine and WAY100635 was faster in LR than in
HR rats. The described effects were receptor specific. A
model explaining the data is presented.
Conclusions These data demonstrate that LR and HR rats
differ in their sensitivity to serotonergic drugs that act at 5-
HT3, 5-HT2 and 5-HT1A receptors. The implications of
these individual differences for individual-specific treat-
ment of substance abuse are briefly discussed.
Keywords Avoidancebehaviour.Individualdifferences.
Serotoninpharmacology.Serotonergicreceptors.
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Introduction
Serotonin (5-hydroxytryptamine, 5-HT) is believed to be
involved in the control of a variety of personality traits,
including impulsivity, risk taking behaviour (Coccaro 1989;
Mehlman et al. 1994) and sensation seeking (Zuckerman
1993, 1996; Netter et al. 1996; Roberti 2004; Pascual et al.
2007). Sensation seeking describes a personality trait
characterised by voluntary participation in activities involv-
ing personal risk (Zuckerman and Neeb 1979). In humans,
individual differences in sensation seeking predict individ-
ual differences in vulnerability to psychiatric disorders like
depression and schizophrenia (Dervaux et al. 2001; Laget et
al. 2006) and to drug abuse (Patkar et al. 2004; Kelly et al.
2006). It has previously been reported that individual
differences in the exploratory response to a novel environ-
ment in rats can predict their neurochemical and behav-
ioural response to cocaine and amphetamine (Piazza et al.
1989; Hooks et al. 1991, 1992; Cools et al. 1997; Ranaldi
et al. 2001; Chefer et al. 2003; Verheij et al. 2008).
Moreover, rats that are marked by a differential exploration
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behavioural response in animal models of schizophrenia
(Ellenbroek et al. 1995; Ellenbroek and Cools 2002). On
the basis of these and related studies, it has been suggested
that enhanced novelty seeking in rats resembles sensation
seeking in humans (Dellu et al. 1996; Cools and Ellenbroek
2002; Ballaz et al. 2007a, b, c).
In the present study, we used two types of rat that are
known to differ in novelty seeking. Rats that are marked by
a high level of exploration in a new environment are
labelled high responders (HR) to novelty, whereas rats that
are marked by a low level of exploration in a new
environment are labelled low responders (LR) to novelty
(Cools et al. 1990, 1993; Cools and Ellenbroek 1996, 2002;
Cools and Gingras 1998). It has repeatedly been shown that
environmental challenges like novelty or pharmacological
challenges like cocaine increase accumbal dopamine levels
more strongly in HR than in LR rats (Hooks et al. 1991,
1992; Saigusa et al. 1999; Verheij and Cools 2007, 2008;
Verheij et al. 2008). Given that serotonergic agents are
known to change the release of dopamine (Kilpatrick et al.
1996; De Deurwaerdere and Spampinato 1999; Ichikawa
and Meltzer 2000), it is hypothesised that HR and LR rats
differ in their sensitivity to these agents. Because individual
differences in sensitivity to serotonergic agents have
frequently been reported in humans (Lerer and Macciardi
2002; Pickar 2003; Bolonna et al. 2004; Lane et al. 2005;
McMahon et al. 2006), rat studies are expected to
contribute to our knowledge of the neuronal substrates that
underlie these individual differences. In addition, rat studies
may help to identify which subjects are sensitive to a
particular serotonergic therapy and which subjects are not.
The aim of the present study was to investigate whether
HR and LR rats differ in their behavioural response to
serotonergic agents. These agents are known to alter the
behavioural response on the elevated T-maze. The elevated
T-maze consists of one enclosed arm perpendicular to two
open arms (Viana et al. 1994). Rats are placed at the distal
end of the enclosed arm, and the time to enter one of the
open arms (with four paws) is scored. Drugs that mimic the
action of serotonin increase the time to approach the open
arms (Graeff et al. 1996a, b 1998; Mora et al. 1997; Viana
et al. 1997), whereas drugs that block the action of
serotonin exert opposite effects (Gargiulo et al. 1996; Mora
et al. 1997; Graeff et al. 1998). Behavioural experiments
have revealed that the avoidance of the open arms increases
after a systemic injection of 5-HT releasers like d-fenflur-
amine (Graeff et al. 1996a, b, 1997), 5-HT3 agonists like
SR77227A (Andrews and File 1992) and 5-HT2 agonists
like DOI (Peng et al. 2004; Bull et al. 2004) and mCPP
(Mora et al. 1997; Graeff et al. 1998; Zangrossi et al. 2001).
Interestingly, 5-HT1A agonists like 8-OH-DPAT have been
found to increase (Critchley and Handley 1987; Kshama et
al. 1990; Treit et al. 1993) or to decrease (Dunn et al. 1989;
Collinson and Dawson 1997) avoidance behaviour (see also
“Discussion”). Additional experiments have also revealed
that the avoidance of the open arms decreases after a
systemic injection of 5-HT3 antagonists like ondansetron
(Filip et al. 1992; Brioni et al. 1994; Sonavane et al. 2002)
and 5HT2 antagonists like ritanserin (Critchley and Han-
dley 1987; Mora et al. 1997; Graeff et al. 1998; Zangrossi
et al. 2001). Finally, the 5-HT1A antagonist WAY100635
has been found to increase rather than to decrease the
avoidance of the open arms (Collinson and Dawson 1997;
Peng et al. 2004).
The present study showed that HR and LR rats indeed
differed in their sensitivity to all of the serotonergic agents
that are listed above.
Methods
Animals Adult male Wistar rats (180–220 g at the start of
the experiments) were used. These animals were reared in
the central animal house of the Radboud University of
Nijmegen, The Netherlands. Initially, rats were housed in
groups of three per cage in a temperature-controlled
environment (20±2°C) under a 12/12 h light/dark cycle
(lights on at 0730 hours). Food (Ssniff) and water were
freely available at all time, except during the open-field and
T-maze test (see below). Rats were isolated 3 or 4 days
prior to the open-field selection (Cools et al. 1990). The
experiments were performed in accordance with institu-
tional, national and international policies on animal care
and welfare. All procedures were in agreement with the
NRC (National Research Council) 2003 guidelines for the
care and use of mammals in neuroscience and behavioural
research.
Open-field selection Half an hour before the open-field
selection, rats were placed in the experimental room to get
accustomed to the new environment. Next, a rat was
placed on a novel open field, which consisted of a black
table (160×160 cm) made of Perspex (Cools et al. 1990).
The table, which was 70 cm above the ground, was
surrounded by a neutral environment. Light intensity was
170 lx at the middle of the open field. Once the rat
was placed in the centre of the open field, its behaviour
was recorded for 30 min using a computerised automated
tracking system as described by Cools et al. (1990).
Selection parameters were ambulation and habituation
time. Ambulation was defined as the total distance
travelled (cm) in 30 min. Habituation time was defined
as the period (s) from the start of the selection until the
moment the rat showed no locomotor activity for at least
90 s. Rats that habituated in less than 480 s and walked
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1990, 1997). Rats that habituated in more than 840 s and
travelled more than 6,000 cm were classified as HR (Cools
et al. 1990, 1997). The selection procedure took place
between 0900 and 1800 hours. The table was cleaned with
70% alcohol after each rat.
Elevated T-maze Seven days after exposure to the open field,
rats were tested on the elevated T-maze. The elevated T-maze
was adapted from the elevated plus-maze (Viana et al. 1994)
and the procedure to test our rats (see “Introduction”)w a s
slightly modified from Graeff et al. (1996a, b). The arms of
the T-maze were of equal dimensions (50×10 cm). The
enclosed arm contained a wall of 40 cm, and the two open
arms were surrounded by a rim of 1 cm. The three arms were
connected by a central square (10×10 cm). Light intensity
was 2.5 lx at the central square.
Twenty-five min before the first exposure to the T-maze,
rats received a single injection of a particular serotonergic
agent or a combination of serotonergic agents (volume,
1 ml/kg, i.p.), whereafter the rats were left undisturbed in
their home cage. Different rats were used for each dose of
every serotonergic agent or each combination of serotoner-
gic agents. Twenty-five min after the injection, rats were
placed at the distal end of the enclosed arm facing the
central square, and the time to enter one of the open arms
(with four paws) was recorded. The time to avoid the open
arms was assessed in each of five consecutive trials (inter-
trial interval, 10 min). All rats were removed from the
elevated T-maze once they reentered the enclosed arm. A
cut-off time of 600 s was used. The T-maze was cleaned
with 70% alcohol after each trial. All experiments were
performed between 0900 and 1400 hours (Griebel et al.
1993).
Drugs The following drugs were used: 5-HT1A antagonist—
WAY100635 (N-{2-[4-(2-methoxyphenyl)-1-piperazinyl]
ethyl}-N-(2-pyridinyl)cyclo-hexanecarboxamide trihydro-
chloride); 5-HT1A agonist—8-OH-DPAT (8-hydroxy-2-(di-
N-propylamino)-tetralin); 5-HT2A/C antagonist—ritanserin
(6-[2-[bis(4-flourophenyl)methylene]-1-piperidenyl]ethyl]-7-
methyl-5H-thiazolo[3,2-a]pyri-midin-5-one); 5-HT2(A)/C
agonists—DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-amino-
propane) and mCPP (1-(3-chlorophenyl)-piperazine
hydrochloride); 5-HT3 agonist—SR57227A (4-amino-1-(6-
chloro-2-pyridyl)-piperidine hydrochloride); 5-HT releaser
and reuptake inhibitor—d-fenfluramine ((+)-N-ethyl-α-
methyl-m-[trifluoromethyl]-phenethylamine). All these drugs
were purchased from Sigma. The 5-HT3 antagonist ondan-
setron (1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-
imidazol-1-yl)methyl]-4H-carbazol-4-one) was purchased
from Glaxo. The drugs were chosen because they have been
found to affect behaviour in the elevated plus-maze and T-
maze (see “Introduction”). To our knowledge, no plus-maze
or T-maze experiments have been performed with
SR57227A, but it has been shown to produce other
behavioural effects at the doses that were applied
(Poncelet et al. 1995). All drugs were dissolved in saline.
Ritanserin was dissolved in saline with a drop of acetic
acid, and the pH was adjusted with sodium hydroxide
(Schreiber et al. 1998; Cayetanot et al. 2001). In order to
maintain the levels of stress as low as possible, rats
received their injection only once before the first trial and
not prior to every trial (Viana et al. 1994;G r a e f fe ta l .
1996a, b). In those cases where a particular agonist or
antagonist changed avoidance behaviour, a cocktail of this
drug with, respectively, an antagonist or agonist (volume,
1 ml/kg, i.p.) was also injected.
Statistical analysis Data were analysed using a two-way
ANCOVA with type of rat and treatment as independent
factors and trials as a covariate. Where appropriate, this test
was followed by a one-way ANCOVA and post hoc LSD
analysis. A total number of 511 rats were exposed to the T-
maze. Extreme values (values more than three times the
interquartile range) were identified using the explore
function of SPSS 12.0.1 and excluded from analysis
(Tuinstra et al. 2000). Thirty-eight rats (7% of the total
number of rats) were excluded at one or more trials. The n
value (see Figs. 1, 2, 3, 4 and 5) represent the number of
rats included on trial 5 (number of rats, 509−38=471). A
probability level of 0.05 was considered to be statistically
significant.
Results
Open-field selection The open-field selection procedure
revealed 24% LR (n=249) rats and 25% HR (n=260) rats.
The average distance travelled in 30 min (± SEM) was
3,624±88 cm in LR rats and 8,316±150 cm in HR rats. The
average habituation time (±SEM) was 324±16 s in LR rats
and 1,310±29 s in HR rats. All efforts were made to
include the rats that did not fulfil the criteria (n=531) in
other studies (Verheij et al. 2007).
Saline The duration of avoidance of the open arms was larger
insaline-treatedLRratsthaninsaline-treatedHRrats(Figs.1,
2, 3 and 4—ANCOVA: type effect, F(1,90)=28.73,p<0.001).
The duration of avoidance behaviour was similar between
the two types of rat during trials 1 and 2. During the
remaining trials, LR rats were marked by more avoidance
behaviour than HR rats. This larger increase of avoidance
behaviour in LR rats compared to HR rats was also observed
under naive conditions (data not shown).
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SR57227A differentially affected the duration of avoidance
behaviour in LR and HR rats (ANCOVA: type×treatment
effect, F(3,341)=13.01, p<0.001). SR57227A increased
avoidance behaviour in both LR (Fig. 1a—ANCOVA:
treatment effect, F(3,172)=11.56, p<0.001) and HR rats
(Fig. 1b—ANCOVA: treatment effect, F(3,168)=19.80,
p<0.001). In LR rats, all doses of SR57227A increased
avoidance behaviour (Fig. 1a—0 vs 1 mg/kg, p=0.010; 0
vs 2 mg/kg, p<0.001; 0 vs 3 mg/kg, p=0.005), whereas
only the highest dose of this drug increased avoidance
behaviour in HR rats (Fig. 1b—0 vs 1 mg/kg, n.s.; 0 vs
2 mg/kg, n.s.; 0 vs 3 mg/kg, p<0.001). In addition,
SR57227A increased the duration of avoidance already at
trials 1–4 in LR rats (Fig. 1a), but only at trials 3–5i nH R
rats (Fig. 1b). Figure 1 also illustrates that the 5-HT3
antagonist ondansetron had differential effects in LR and
HR rats (ANCOVA: type×treatment effect, F(2,286)=6.82,
p=0.001). Ondansetron decreased the duration of avoidance
behaviour in LR rats (Fig. 1c—ANCOVA: treatment effect,
F(2,132)=8.87, p<0.001; 0 vs 0.01 mg/kg, p=0.026; 0 vs
0.1 mg/kg, p<0.001), but not in HR rats (Fig. 1d—ANCOVA:
treatment effect, n.s.; 0 vs 0.01 mg/kg, n.s.; 0 vs 0.1 mg/kg,
n.s.; and 0 vs 5.0 mg/kg, n.s.). Ondansetron attenuated the
SR57227A-induced increase of avoidance in both LR rats
(Fig. 1e—SR57227A vs ondansetron + SR57227A:
ANCOVA, treatment effect, F(1,71)=6.76, p=0.011) and HR
rats (Fig. 1f—SR57227A vs ondansetron + SR57227A:
Fig. 1 Effects of the 5-HT3
agonist SR57227A (a, b), the
5-HT3 antagonist ondansetron
(c, d) and the combination of
both (e, f) on the duration of
avoidance of the open arms in
LR (left) and HR (right) rats.
Asterisks Significant change vs
saline. Number signs Significant
decrease vs SR57227A
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agonists DOI (a, b) and mCPP
(c, d), the 5-HT2A/C antagonist
ritanserin (e, f) and the
combination of mCPP and
ritanserin (g, h) on the duration
of avoidance of the open arms in
LR (left) and HR (right) rats.
Asterisks Significant change vs
saline. Number signs Significant
increase/decrease vs mCPP
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the duration of avoidance induced by the combination of
ondansetron and SR57227A differed from the duration of
avoidance induced by ondansetron alone in LR rats (Fig. 1e—
ondansetron + SR57227A vs ondansetron: ANCOVA,
treatment effect, F(1,65)=13.87, p<0.001) and in HR rats
(Fig. 1f—ondansetron + SR57227A vs ondansetron:
ANCOVA, treatment effect, F(1,62)=6.38, p=0.014).
5-HT2 drugs Figure 2 illustrates that the 5-HT2A/C
agonist DOI differentially affected the duration of avoid-
ance behaviour in LR and HR rats (ANCOVA: type×
treatment effect, F(2,294)=7.69, p=0.001). DOI decreased
avoidance behaviour in LR rats (Fig. 2a—ANCOVA:
treatment effect, F(2,156)=3.30, p=0.040; 0 vs 0.5 mg/kg,
p=0.039; 0 vs 1 mg/kg, p=0.041), but increased avoid-
ance behaviour in HR rats (Fig. 2b—ANCOVA: treatment
effect, F(2,137)=5.83, p=0.004; 0 vs 0.5 mg/kg, n.s.; 0 vs
1m g / k g ,p=0.001). Since a decrease in the duration of
avoidance behaviour following a 5-HT2 agonist was
unexpected (see “Introduction”), the effects of an addi-
tional 5-HT2 agonist were tested. The effects of the 5-
HT2C agonist mCPP were similar to the effects of DOI.
Figure 2 shows that mCPP had differential effects in LR
and HR rats (ANCOVA: type×treatment effect, F(2,265)=
12.10, p<0.001). Similar to DOI, mCPP decreased
Fig. 3 Effects of the 5-HT1A
agonist 8-OH-DPAT (a, b), the
5-HT1A antagonist
WAY100635 (c, d) and the
combination of both (e, f)o n
the duration of avoidance of the
open arms in LR (left) and HR
(right) rats. Asterisks Significant
change vs saline. Number signs
Significant decrease vs
WAY100635
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F(2,131)=3.72, p=0.027; 0 vs 0.2 mg/kg, p=0.026; 0 vs
0.4 mg/kg, p=0.040), whereas mCPP increased avoidance in
HR (Fig. 2d—ANCOVA: treatment effect, F(2,133)=13.12,
p<0.001; 0 vs 0.2 mg/kg, n.s.; 0 vs 0.4 mg/kg, p<0.001).
Figure 2 also illustrates that the 5-HT2A/C antagonist
ritanserin had differential effects in LR and HR rats
(ANCOVA: type×treatment effect, F(3,428)=3.59, p=0.014).
Ritanserin decreased the duration of avoidance behaviour
in LR (Fig. 2e—ANCOVA: treatment effect, F(3,192)=4.68,
p=0.004; 0 vs 0.1 mg/kg, n.s.; 0 vs 0.2 mg/kg, n.s.; 0 vs
0.3 mg/kg, p<0.001), but not in HR (Fig. 2f—ANCOVA:
treatment effect, n.s.; 0 vs 0.1 mg/kg, n.s.; 0 vs 0.2 mg/kg,
n.s.; 0 vs 0.3 mg/kg, n.s.; 0 vs 0.5 mg/kg, n.s.). Both the
mCPP-induced decrease of avoidance behaviour in LR rats
and the mCPP-induced increase of avoidance behaviour in
HR rats were attenuated by ritanserin (LR rats (Fig. 2g)—
mCPP vs mCPP + ritanserin: ANCOVA, treatment effect,
F(1,79)=11.72, p=0.001; HR rats (Fig. 2h)—mCPP vs
mCPP + ritanserin: ANCOVA, treatment effect, F(1,73)=
4.87, p=0.030). Finally, the duration of avoidance induced by
the combination of ritanserin and mCPP differed from the
duration of avoidance induced by ritanserin alone in LR
(Fig. 2g—mCPP + ritanserin vs ritanserin: ANCOVA,
treatment effect, F(1,92)=5.68, p=0.019), but not in HR rats
(Fig. 2h—mCPP + ritanserin vs ritanserin: ANCOVA,
treatment effect, n.s.).
5-HT1 drugs The 5-HT1A agonist 8-OH-DPAT had differ-
ential effects on the duration of avoidance behaviour in LR
and HR rats (ANCOVA: type×treatment effect, F(3,385)=
4.19, p=0.006). Figure 3 illustrates that 8-OH-DPAT de-
creased avoidance behaviour in LR rats (Fig. 3a—ANCOVA:
treatment effect, F(3,163)=2.88, p=0.038; 0 vs 0.1 mg/kg,
p=0.011; 0 vs 0.3 mg/kg, p=0.023; 0 vs 0.5 mg/kg,
p=0.060), whereas it increased avoidance behaviour in HR
rats (Fig. 3b—ANCOVA: treatment effect, F(3,221)=8.07,
p<0.001; 0 vs 0.1 mg/kg, n.s.; 0 vs 0.3 mg/kg, p<0.001;
and 0 vs 0.5 mg/kg, n.s.). Figure 3 also shows that the 5-
HT1A antagonist WAY100635 had differential effects in LR
and HR rats (ANCOVA: type×treatment effect, F(3,332)=7.89,
p<0.001). WAY100635 increased avoidance behaviour in
both LR rats (Fig. 3c—ANCOVA: treatment effect, F(3,166)=
12.49, p<0.001; 0 vs 0.01 mg/kg, p=0.011; 0 vs 0.05 mg/kg,
p=0.052; 0 vs 0.1 mg/kg, p<0.001) and HR rats (Fig. 3d—
ANCOVA: treatment effect, F(3,165)=11.76, p<0.001; 0 vs
0.01 mg/kg, p<0.001; 0 vs 0.05 mg/kg, p<0.001; 0 vs
0.1 mg/kg, p=0.001). However, WAY100635 increased the
duration of avoidance already at trials 1–4i nL Rr a t s
(Fig. 3c), but only at trials 2–5i nH Rr a t s( F i g .3d). The
WAY100635-induced increase of avoidance was counteracted
by 8-OH-DPAT in both LR rats (Fig. 3e—WAY100635 vs
8-OH-DPAT + WAY100635: ANCOVA, treatment effect,
F(1,79)=33.02, p<0.001) and HR rats (Fig. 3f—
WAY100635 vs 8-OH-DPAT + WAY100635: ANCOVA,
Fig. 4 Effects of the 5-HT
reuptake inhibitor/5-HT releaser
d-fenfluramine (a, b) and the
combination of the 5-HT3
antagonist ondansetron and
d-fenfluramine (c, d) on the
duration of avoidance of the
open arms in LR (left) and HR
(right) rats. Asterisks Significant
change vs saline. Number signs
Significant decrease vs
d-fenfluramine
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duration of avoidance following the combination of 8-
OH-DPAT and WAY100635 was significantly different
from the duration of avoidance following 8-OH-DPAT
alone in LR rats (Fig. 3e—8-OH-DPAT + WAY100635 vs
8-OH-DPAT: ANCOVA, treatment effect, F(1,83)=4.68, p=
0.034) and in HR rats (Fig. 3f—8-OH-DPAT +
WAY100635 vs 8-OH-DPAT: ANCOVA, treatment effect,
F(1,77)=4.02, p=0.049).
d-Fenfluramine Figure 4 illustrates that the 5-HT releaser/
reuptake blocker d-fenfluramine differentially affected the
duration of avoidance behaviour in LR and HR rats
(ANCOVA: type×treatment effect, F(2,285)=3.75, p=0.026).
Although d-fenfluramine increased the duration of avoidance
behaviour in both LR rats (Fig. 4a—ANCOVA: treatment
effect, F(2,150)=7.50, p=0.001; 0 vs 0.1 mg/kg, p=0.034; 0 vs
0.3 mg/kg, p<0.001) and HR rats (Fig. 4b—ANCOVA:
treatment effect, F(2,134)=8.48, p<0.001; 0 vs 0.1 mg/kg,
p<0.001; 0 vs 0.3 mg/kg, p=0.006), post hoc analysis revealed
that, similar to SR57227A, d-fenfluramine already increased
avoidance behaviour at trials 1–3i nL R( F i g .4a), but only at
trials 3–5i nH Rr a t s( F i g .4b). Because our data suggest that
the action of d-fenfluramine may be due to stimulation of 5-
HT3 receptors (see “Discussion”), we also investigated the
effects of the 5-HT3 antagonist ondansetron on the d-
fenfluramine-induced changes of avoidance. Ondansetron was
found to attenuate the d-fenfluramine-induced increase of
avoidance in both LR rats (Fig. 4c—d-fenfluramine vs
ondansetron + d-fenfluramine: ANCOVA, treatment effect,
F(1,95)=4.85, p=0.030) and HR rats (Fig. 4d—d-fenfluramine
vs ondansetron + d-fenfluramine: ANCOVA, treatment effect,
F(1,77)=11.29, p=0.001). The duration of avoidance induced
by the combination of ondansetron and d-fenfluramine was
different from the duration of avoidance induced by ondanse-
tron alone in LR rats (Fig. 4c—ondansetron + d-fenfluramine
vs d-fenfluramine: ANCOVA, F(1,78)=28.66,p<0.001) and in
HR rats (Fig. 4d—ondansetron + d-fenfluramine vs
d-fenfluramine: ANCOVA, treatment effect, F(1,56)=7.46,
p=0.008).
5-HT1 and 5-HT2/5-HT3 drugs In order to investigate
whether the behavioural effects of WAY100635, which is
suggested to act at presynaptic 5-HT1A receptors (see
“Discussion”), could be inhibited by an antagonist that is
suggested to act at postsynaptic 5-HT2 or 5-HT3 receptors
(see “Discussion”), rats were treated with a cocktail of
WAY100635 and ritanserin or WAY100635 and ondansetron.
The 5-HT2A/C antagonist ritanserin did not inhibit the
WAY100635-induced increase of avoidance in either LR rats
(Fig. 5a—WAY100635 vs ritanserin + WAY100635:
ANCOVA, treatment effect, n.s.) or HR rats (Fig. 5b—
WAY100635 vs ritanserin + WAY100635: ANCOVA, treat-
ment effect, n.s.). The duration of avoidance induced by the
combination of ritanserin and WAY100635 differed from
the duration of avoidance induced by ritanserin alone in
Fig. 5 Effects of the 5-HT2A/C
antagonist ritanserin (a, b) and
the 5-HT3 antagonist
ondansetron (c, d) on the
WAY100635-induced increase
of the duration avoidance
behaviour in LR (left) and HR
(right) rats. Asterisks Significant
change vs saline. Number signs
Significant decrease vs
WAY100635
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ANCOVA, treatment effect, F(1,107)=37.82, p<0.001) and in
HR (Fig. 5b—ritanserin + WAY100635 vs ritanserin:
ANCOVA, treatment effect, F(1,83)=15.42, p<0.001). The
5-HT3 antagonist ondansetron inhibited the WAY100635-
induced increase of avoidance in both LR rats (Fig. 5c—
WAY100635 vs ondansetron + WAY100635: ANCOVA,
treatment effect, F(1,73)=40.48, p<0.001) and HR rats
(Fig. 5d—WAY100635 vs ondansetron + WAY100635:
ANCOVA, treatment effect, F(1,74)=6.51, p=0.013). The
duration of avoidance induced by the combination of
ondansetron and WAY100635 differed from the duration of
avoidance induced by ondansetron alone in LR rats (Fig. 5c—
ondansetron + WAY100635 vs ondansetron: ANCOVA,
treatment effect, F(1,63)=13.11, p=0.001) and in HR rats
(Fig. 5d—ondansetron + WAY100635 vs ondansetron:
ANCOVA, treatment effect, F(1,61)=6.70, p=0.012).
Discussion
Summary of the results
The aim of the present study was to assess individual
differences in the sensitivity to serotonergic drugs between
rats that were characterised as HR and LR to novelty. The
5-HT3 agonist SR57227A increased the duration of
avoidance behaviour in both types of rat (Fig. 1a/b).
However, higher doses of SR57227A were required to alter
the duration of avoidance behaviour in HR than in LR rats
(Fig. 1a/b). The 5-HT3 antagonist ondansetron decreased
avoidance behaviour in LR rats, but had no effects in HR
rats (Fig. 1c/d). Remarkably, the 5-HT2 agonists mCPP and
DOI decreased the duration of avoidance behaviour in LR
rats, but increased the duration of this behaviour in HR rats
(Fig. 2a–d). The 5-HT2 antagonist ritanserin decreased
avoidance behaviour in LR rats, but had no effects in HR
rats (Fig. 2e/f). The 5-HT1A agonist 8-OH-DPAT decreased
the duration of avoidance behaviour in LR rats, but
increased the duration of this behaviour in HR rats
(Fig. 3a/b). Both the 5-HT1A antagonist WAY100635
(Fig. 3c/d) and the serotonin releaser/reuptake inhibitor d-
fenfluramine (Fig. 4a/b) increased avoidance behaviour in
both types of rat. However, the onset of the effects of
WAY100635 (Fig. 3c/d) and d-fenfluramine (Fig. 4a/b) was
faster in LR than in HR rats. The same held true for the
onset of the effects of SR57227A (Fig. 1a/b). Finally, the
duration of avoidance behaviour was larger in control LR
rats compared to control HR rats (Figs. 1, 2, 3 and 4). These
data demonstrate that LR and HR rats differ in their
sensitivity to all serotonergic drugs that were tested. Apart
from the direction of the effects of DOI and mCPP in LR
rats, the direction of the effects of the remaining serotonergic
agents nicely fit in with the available literature (for
reference, see “Introduction”).
Below, a model will be presented to explain our results.
The model is based on the original finding by Graeff et al.
that the duration of avoidance of the open arms becomes
larger as synaptic serotonin levels increase (Graeff et al.
1996a, b, 1998; Mora et al. 1997; Viana et al. 1997). The
finding that d-fenfluramine, a drug that is known to
increase the levels of serotonin in the synapse (Consolo et
al. 1979; Gundlah et al. 1997), increases the duration of
avoidance behaviour in both LR (Fig. 4a) and HR (Fig. 4b)
rats is nicely in line with the previously reported findings
by Graeff et al.
Model explaining the results
5-HT3 drugs The effects of SR57227A in HR rats were
inhibited by a behaviourally silent dose (5.0 mg/kg) of the
5-HT3 antagonist ondansetron (Fig. 1f), suggesting that the
SR57227A-induced changes in the duration of avoidance
behaviour are mediated by 5-HT3 receptors. The fact that
SR57227A resulted in an increase of avoidance (Fig. 1a/b)
indicates that this agonist acts at postsynaptic 5-HT3
receptors. It has recently been shown that LR and HR rats
do not differ in their 5-HT3 receptor expression (Ballaz et
al. 2007a). Combining this previous finding with the
present finding that higher doses of SR57227A were
required to alter the duration of avoidance behaviour in
HR than in LR (Fig. 1a/b) results in the notion that LR rats
are characterised by postsynaptic 5-HT3 receptors that are
more sensitive than those of HR rats (Fig. 6). This is
supported by the finding that all doses of the 5-HT3
antagonist ondansetron decreased the duration of avoidance
behaviour in LR rats (Fig. 1c), whereas none of the tested
doses of this drug decreased the duration of avoidance
behaviour in HR rats (Fig. 1d).
5-HT2 drugs In HR rats, the effects of the 5-HT2C agonist
mCPP were blocked by a behaviourally silent dose (0.3 mg/kg)
of the 5-HT2A/C antagonist ritanserin (Fig. 2h). These data
suggest that the mCPP-induced changes in the duration of
avoidance behaviour are mediated by 5-HT2C receptors. The
results of the 5-HT2A/C agonist DOI were similar to the
results of mCPP, indicating that the effects of DOI were also
mediated by 5-HT2C receptors. The fact that both mCPP and
DOI resulted in an increase of avoidance in HR (Fig. 2b/d),
but not in LR (Fig. 2a/c) indicates that the serotonergic
projection regions of HR rats are marked by more or more
sensitive postsynaptic 5-HT2C receptors than the serotonergic
projection regions of LR rats (Fig. 6). The finding that the 5-
HT2C agonists mCPP and DOI decreased the duration of
avoidance behaviour in LR (Fig. 2a/c) suggest that these drugs
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of serotonergic activity cannot simply be explained by an
action at presynaptic 5-HT2 autoreceptors because 5-HT2
receptors have found to be located postsynaptically only
(Barnes and Sharp 1999). Recent studies, however, have
revealed that the synaptic serotonergic activity is reduced after
stimulation of postsynaptic 5-HT2 receptors that are located
on inhibitory GABAergic interneurons in the dorsal raphe
(Liu et al. 2000;B o o t h m a ne ta l .2003; Serrats et al. 2005;
Boothman and Sharp 2005). These GABAergic neurons are
supposed to be part of a feedback loop. We, therefore,
hypothesise that LR rats exhibit more or more sensitive 5-
HT2C receptors that are located on this feedback loop than
HR rats (Fig. 6). Ritanserin decreased the duration of
avoidance behaviour in LR (Fig. 2e), but not in HR
(Fig. 2f) rats. Given the lack of effects of mCPP at the
postsynaptic 5-HT2C receptors of the serotonergic projection
regions of LR rats (see above), these data can only be
explained by an action of ritanserin in the serotonergic
projection regions containing postsynaptic 5-HT2A receptors
(Fig. 6). Our data indicate that LR rats are marked by more or
more sensitive postsynaptic 5-HT2A receptors that belong to
t h i sf e e d f o r w a r dl o o pt h a nH Rr a t s( F i g .6). The fact that a
behaviourally silent dose (0.1 mg/kg) of the 5-HT2A agent
ritanserin inhibited the effects of the 5-HT2C agent mCPP in
LR (Fig. 2g) strongly suggests that the postsynaptic 5-HT2A
receptors that belong to the feedforward loop of these rats are
located on the same pathway as the 5-HT2C receptors that
belong to the feedback loop of these rats (Fig. 6).
5-HT1 drugs The effects of WAY100635 during trials 1
and 2 in LR rats were inhibited by the 5-HT1A agonist 8-
OH-DPAT (Fig. 3e), which in itself was not effective during
these trials (Fig. 3a), suggesting that the WAY100635-
induced changes in the duration of avoidance behaviour are
mediated by 5-HT1A receptors. WAY100635 has been
found to increase avoidance behaviour only when it acts
presynaptically (Dos Santos et al. 2005; Dos-Santos et al.
2008). The finding that WAY100635 increases avoidance in
LR (Fig. 3c) and in HR (Fig. 3d) indicates that inhibitory
presynaptic 5-HT1A receptors are present in both types of
rat (Fig. 6). The 5-HT1A agonist 8-OH-DPAT increased the
duration of the avoidance behaviour in HR (Fig. 3b), but
not in LR (Fig. 3a) rats. 8-OH-DPAT has been reported to
result in an increase of avoidance behaviour only when its
acts postsynaptically (Dos-Santos et al. 2008; Viana et al.
2008). Therefore, our data suggest the presence of more or
more sensitive postsynaptic 5-HT1A receptors in HR than
in LR rats (Fig. 6). The fact that a behaviourally silent dose
(0.5 mg/kg) of the postsynaptic acting 5-HT1A agent 8-
OH-DPAT inhibited the effects of the presynaptic acting 5-
HT1A agent WAY100635 in HR (Fig. 3f) illustrates that the
neurons that contain pre- and postsynaptic 5-HT1A
receptors in these rats are located on the same pathway
(Fig. 6). A presynaptic action of 8-OH-DPAT has repeat-
edly been reported to result in a decrease of avoidance
(Sena et al. 2003; Dos Santos et al. 2005; Vicente et al.
2008). The finding that 8-OH-DPAT decreased the duration
of avoidance in LR (Fig. 3a) can be explained by the
already discussed presence of presynaptic 5-HT1A autor-
eceptors in these rats (Fig. 6).
Combination of 5-HT1, 5-HT2 and 5-HT3 drugs The
finding that the 5-HT2A/C antagonist ritanserin did not inhibit
the WAY100635-induced increase in the duration of avoidance
behaviour in either LR (Fig. 5a) or HR (Fig. 5b) rats suggests
that the pathway that contains presynaptic 5-HT1A receptors
does not contain postsynaptic 5-HT2A or 5-HT2C receptors
(Fig. 6). The avoidance-increasing effects of WAY100635
were inhibited by the dose of 0.1 mg/kg of the 5-HT3
antagonist ondansetron in both LR (Fig. 5c) and HR (Fig. 5d)
rats. This dose of ondansetron itself did not change avoidance
behaviour during trials 1–2i nL Rr a t s( F i g .1c) and during
trials 1–5i nH Rr a t s( F i g .1d). Our data, therefore, indicate
that the presynaptic 5-HT1A receptors and the postsynaptic 5-
HT3 receptors belong to the same pathway (Fig. 6).
d-Fenfluramine The effects of d-fenfluramine appeared to
be very similar to the effects of the 5-HT3 agonist
SR57227A. More specifically, both drugs increased the
duration of avoidance behaviour in HR and in LR rats
(Figs. 1 and 4), whereas the 5-HT2C agonists (DOI and
mCPP) and the 5-HT1A agonist (8-OH-DPAT) increased
the duration of avoidance behaviour in HR rats, but
decreased the duration of avoidance behaviour in LR rats
(Figs. 2 and 3). Similar to the onset of the effects of
SR57227A, the onset of the effects of d-fenfluramine was
faster in LR (Fig. 1a vs Fig. 4a—trials 1–3) than in HR
(Fig. 1b vs Fig. 4b—trials 3–5) rats. This striking similarity
between the effects of the serotonin reuptake inhibitor/
serotonin releaser d-fenfluramine and SR57227A suggests
that the action of d-fenfluramine is mediated mainly via
postsynaptic 5-HT3 receptors and not (or less) via
postsynaptic 5-HT1A or 5-HT2A/C receptors (see also
Consolo et al. 1994). This notion is supported by our
finding that the avoidance-increasing effects of d-fenflur-
amine during trials 1–2 in LR rats and during trials 3–5i n
HR rats were strongly inhibited by the dose of 0.1 mg/kg of
the 5-HT3 antagonist ondansetron (Fig. 4c/d), which in
itself was not effective at these trials (Fig. 1c/d).
Saline Injection stress and exposure to a novel behavioural set-
up have both been found to increase synaptic serotonin levels
(Adell et al. 1997; Thomas et al. 2000). The finding that the
duration of avoidance of the open arms increased more
strongly in naive or saline-treated LR than in naive or saline-
450 Psychopharmacology (2009) 205:441–455treated HR (Figs. 1, 2, 3 and 4) indicates that serotonin levels
increase more strongly in challenged LR rats than in
challenged HR rats. This behavioural finding nicely fits in
with the neurochemical finding of Piazza et al. (1991b)t h a t
the brain levels of serotonin are relatively large in LR
compared to HR rats. Although analysis over all trials clearly
revealed individual differences in avoidance behaviour in
saline-treated LR and HR rats, no individual differences were
found between these two types of rat during the first trial of
the elevated T-maze. This finding confirms the previously
reported finding that a single exposure to the elevated plus-
maze does not result in behavioural differences between LR
and HR rats (Thiel et al. 1999;B a l l a ze ta l .2007b), whereas
repeated exposure does (Ballaz et al. 2007b).
Personality traits explaining the results
Effects are not due to individual differences in anxiety The
elevated T-maze is generally used to measure anxiety related
behaviour (Graeff et al. 1996a, b1 9 9 8 ). Rats bred for high
anxiety behaviour are typically marked by a larger
challenged-induced increase of corticosterone and ACTH
compared to rats bred for low anxiety behaviour (Liebsch et
al. 1998;L a n d g r a fe ta l .1999) .T h ef a c tt h a tc h a l l e n g e dL R
rats have been found to be marked by smaller levels of
corticosterone and ACTH than challenged HR rats (Piazza et
al. 1991a;R o t se ta l .1995, 1996;K a b b a je ta l .2000, 2007)
strongly indicates that the relatively large challenge-induced
increase in the duration of avoidance behaviour in control
LR rats (Figs. 1, 2, 3 and 4) is not due to a relatively large
level of anxiety in these rats. Accordingly, alternative traits
may have caused the serotonin-induced individual differ-
ences in the duration of avoidance behaviour in our rats.
Effects may be due to individual differences in habituation
to a new environment It has previously been hypothesised
that the behavioural response during the first trial of a
particular test may be of a different nature than the
behavioural response during the remaining trials of this test
(File et al. 1993; Ballaz et al. 2007b). In addition to
SR57227A and d-fenfluramine, WAY100635 was found to
result in a larger increase of avoidance behaviour during
trial 1 in LR than in HR rats (Fig. 3). Remarkably, the
remaining drugs (saline, ondansetron, DOI, mCPP, ritan-
serin and 8-OH-DPAT) did not result in individual differ-
ences in avoidance behaviour during the first trial. The fact
that the presynaptic acting agent WAY100635 increased
avoidance behaviour in the same trial as the postsynaptic
acting agent SR57227A fits in with our above-mentioned
notion that the presynaptic 5-HT1A receptors belong to the
same pathway as postsynaptic 5-HT3 receptors (Fig. 6). On
the basis of these considerations, it is suggested that the
pathway containing postsynaptic 5-HT3 receptors (Fig. 6)
is important in mediating the immediate response to a novel
environment, whereas the pathways containing postsynaptic
5HT1A and 5-HT2 receptors (Fig. 6)m a yb em o r e
important in mediating the behavioural response after
reexposure to this environment. Based on the criteria that
were used to select HR and LR rats (see “Methods”), we
hypothesise that the observed individual differences in the
time to approach the open arms of the T-maze are due to
individual differences in exploration of a novel environ-
ment (possible mediated by postsynaptic 5-HT3 receptors)
and habituation to this environment (possibly mediated by
postsynaptic 5-HT1A and 5-HT2 receptors).
Putative contribution of the serotonergic system to the effects
of drugs of abuse
Serotonergic agents have been found to affect the neurochem-
ical and behavioural response to drugs of abuse. These effects
may well be the result of the fact that serotonergic agents can
Fig. 6 Putative serotonergic system of the brain of LR (upper panel)
and HR (lower panel) rats. receptors that stimulate avoidance
behaviour, receptors that reduce avoidance behaviour. > relatively
sensitive receptors, < relatively insensitive receptors
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1996; De Deurwaerdere and Spampinato 1999; Ichikawa
and Meltzer 2000). 5-HT3 antagonists are suggested to be
effective in the treatment of alcohol abuse (Greenshaw
1993; Grant 1995), whereas 5-HT2A antagonists(McMahon
and Cunningham 2001; Davidson et al. 2002; Filip et al.
2004; Bubar and Cunningham 2006) and 5-HT2C agonists
(Fletcher et al. 2004; Filip et al. 2006; Bubar and
Cunningham 2006; Neisewander and Acosta 2007) can
reduce the behavioural effects of cocaine. Finally, systemic
administration of 5-HT1A antagonists and agonists are
known to, respectively, increase and reduce the accumbal
dopamine response to cocaine and amphetamine (Ichikawa
et al. 1995; Andrews et al. 2005). In case serotonergic
agents can be used to treat drug abuse, personalised therapy
is preferred. On the basis of our finding that rats being
selected on a low and high response to novelty differ in their
sensitivity to serotonergic agents, it is hypothesised that the
optimal serotonergic therapy may differ between substance
abusers with a low and a high sensation-seeking score.
Conclusions
HR and LR rats have been found to differ in the expression
of 5-HT6 and 5-HT7 receptors (Ballaz et al. 2007a, c)a s
well as in the levels of serotonin in the brain (Piazza et al.
1991b). The present study provides the original finding
that HR and LR rats also significantly differ in their
sensitivity to serotonergic drugs that act at the level of 5-
HT3, 5-HT2 and 5-HT1 receptors (see Fig. 6). Future
studies using HR and LR rats are required to investigate in
which brain structures these receptors are located. Knowl-
edge about the serotonergic system of high and low
responders to novelty rats may well contribute to our
knowledge about the serotonergic system of high and low
sensation seekers in humans (Dellu et al. 1996;B a l l a ze ta l .
2007a, c). On the basis of our animal studies, it is
hypothesised that the level of sensation seeking in humans
can predict which subjects are vulnerable to a specific
serotonergic therapy and which subjects are not.
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